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Abstract
Thyroid hormones play critical roles in differentiation,
growth and metabolism, but their participation in im-
mune system regulation has not been completely eluci-
dated. Modulation of in vivo thyroid status was used to
carry out an integrative analysis of the role of the
hypothalamus–pituitary–thyroid (HPT) axis in T and B
lymphocyte activity. The participation of the protein
kinase C (PKC) signaling pathway and the release of some
cytokines upon antigenic stimulation were analyzed.
Lymphocytes from hyperthyroid mice displayed higher T-
and B-cell mitogen-induced proliferation, and those from
hypothyroid mice displayed lower T- and B-cell mitogen-
induced proliferation, compared with euthyroid animals.
Reversion of hypothyroid state by triiodothyronine (T3)
administration recovered the proliferative responses. No
differences were found in lymphoid subset balance. Both
total PKC content and mitogen-induced PKC transloca-
tion were higher in T and B cells from hyperthyroid mice,
and lower in cells from hypothyroid mice, compared with
controls. Levels of thyroid-stimulating (TSH) and TSH-
releasing (TRH) hormones were not directly related to
lymphocyte proliferative responses. After immunization
with sheep red blood cells (SRBCs) and re-stimulation, in
vitro spleen cells from hyper- or hypothyroid mice
showed, respectively, increased or decreased production
of interleukin (IL)-2 and interferon (IFN)- cytokines.
Additionally, an increase in IL-6 and IFN- levels was
found in hyperthyroid cells after in vivo injection and in
vitro re-stimulation with lipopolysaccharide (LPS).
Our results show for the first time a thyroid hormone-
mediated regulation of PKC content and of cytokine
production in lymphocytes; this regulation could be
involved in the altered responsiveness to mitogen-induced
proliferation of T and B cells. The results also confirm the
important role that these hormones play in regulating
lymphocyte reactivity.
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Introduction
Homeostatic regulation of immunity involves factors that
are traditionally considered outside the immune system,
including hormones and neurotransmitters. Thyroid
hormones play critical roles in differentiation, growth and
metabolism (Yen 2001). Although thyroid hormone
participation in primary and secondary lymphopoiesis has
been described (for review see Fabris et al. (1995), in
general their effects on the immune system have received
comparatively less attention than those from hormones of
the hypothalamus–pituitary–adrenal axis (Dorshkind &
Horseman 2000, Wang & Klein 2001). This fact could be
related to the dominating role of autoimmunity in the
pathogenesis of thyroid disorders (Pawlikowski et al.
1994).
Interactions between pituitary–thyroid hormones and
the immune system are mainly based on the existence of
receptors for thyreotropic and thyroid hormones on lympho-
cytes or on the frequent immune alterations observed in
physiological and pathological fluctuations of thyroid
hormones. Hypothyroidism in humans, or experimentally
induced hypothyroidism (propylthiouracil (PTU) treat-
ment) and thyroidectomy in rodents, has been shown
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to diminish thymic activity, effects that were reversed
by treatment with thyroid hormones (Fabris et al. 1995).
In addition, hypothyroid experimental conditions lead to
spleen and lymph node involution, as well as to depressed
humoral and cell-mediated immune responses (Chatterjee
& Chandel 1983, Ohashi & Itoh 1994, Klecha et al. 2000).
Restoration of thyroid function, after thiourea-induced
blockade, restored the humoral response to sheep red
blood cells (SRBCs) in birds (Keast & Ayre 1980). More-
over, suppression of cell-mediated immunity in severe
human hypothyroidism, with improvement of lympho-
cyte function during a gradual return to the euthyroid
state, has also been described (Schoenfeld et al. 1995).
Conversely, contradictory results exist in the literature
on the effect of experimental hyperthyroidism on the
humoral and cellular immunity. Thus, either an enhanc-
ing or suppressing effect of primary antibody responses
(Fabris et al. 1995, Klecha et al. 2000) or of T and B
lymphocyte proliferation (Chatterjee & Chandel 1983,
Klecha et al. 2000) was demonstrated in hyperthyroid
conditions. Opposing data could be reflecting differences
among species or among the hormonal treatment estab-
lished. In fact an integrative study of the hypothalamus–
pituitary–thyroid (HPT) axis function has not previously
been performed.
Recent evidence arising from analysis of lymphocyte
development and function in mice with genetic defects in
the expression of thyroid hormones or their receptors
suggested that these hormones are not obligatory for the
development of a normal immune response. Instead, the
hypothesis proposed was that they are involved in main-
taining immune system homeostasis in response to
environmental changes or stress-mediated immuno-
suppression (Davis 1998, Dorshkind & Horseman 2000,
2001). In fact, no alteration in humoral or cell-mediated
immunity was found in dwarf mice with genetic defects in
genes encoding for several anabolic hormones (including
thyroid hormones) or in thyroid hormone-deficient
hyt/hyt knockout mice (Foster et al. 2000). Although
knockout mice studies have demonstrated that hormone
deficiency is not incompatible with life, many of the
effects on peripheral tissues were milder in these animals
than those seen in congenital hypothyroidism (Yen 2001).
On this basis, the aim of this work was to perform an
integrative analysis of the role of HPTstatus on T and B
lymphocyte activation through the in vivo modulation of
thyroid status. In addition, we aimed to study for the first
time the participation of protein kinase C (PKC) intrac-
ellular signaling in thyroid hormone modulation of
lymphocyte proliferation and to examine key cytokine
levels induced by antigen challenge. Here we show a
thyroidal state-mediated regulation of mitogen-induced
lymphocyte proliferation related to the total cellular and
membrane-associated content of PKC and of cytokines




Inbred BALB/c (H-2d) female mice were obtained from
the Instituto de Tecnología Agropecuaria de la República
Argentina (INTA). All animals used were 60–70 days old
and were handled according to the International Regula-
tions for the Care and Use of Laboratory Animals.
In vivo thyroid hormones and anti-thyroid agent treatments
In order to induce high levels of thyroid hormones, mice
were treated with thyroxine (T4) as it is usually used in
normal replacement therapies in hypothyroid patients due
to its higher half-life compared with triiodothyronine
(T3). For this reason T4 displays a constant potency and
prolonged action through its conversion to T3 in periph-
eral tissues. The treatment was performed according to
previously described procedures (Shinohara et al. 2000).
Briefly, BALB/c mice received a subcutaneous injection
of 0·6 µg/g body weight (BW) T4 (Sigma) (dissolved in
0·01 M NaOH, diluted 1:10 with PBS, pH 7·2, and
Millipore filtered) every day for 30 days. In this way
almost undetectable values of thyroid-stimulating hor-
mone (TSH) were obtained. Mice injected with the
vehicle alone were used as controls.
The anti-thyroid drug PTU was chosen for hypothy-
roidism development for two reasons. First, anti-thyroid
drugs are usually used in human hyperthyroidism treat-
ment (Streetman & Khanderia 2003). Secondly, more
drastic treatments, such as surgical or 131I-induced thyroid-
ectomy, also affect immune function (Ohashi & Itoh
1994), with the latter also being genotoxic for lympho-
cytes (Ballardin et al. 2002). To promote low circulating
levels of thyroid hormones in BALB/c mice, PTU was
given in the drinking water (0·5 mg/ml) for 18 days as
previously described (Klecha et al. 2000). The daily-
ingested amount of PTU was approximately 60 µg/g BW
per day.
Reversion of PTU treatment was achieved via T3
administration since this anti-thyroid drug also blocks
peripheral conversion of T4 to T3. For PTU+T3 treat-
ment, animals treated with PTU also received 0·2 µg/g
BW per day of T3 (dissolved in the same vehicle as used
for thyroxine) for the last 6 days of treatment. Control
animals received the vehicle alone.
Cell suspensions and culture conditions
Lymphoid cell suspensions from euthyroid, hyperthyroid,
hypothyroid or PTU+T3-treated animals’ lymph nodes,
spleen or nylon wool purified T cells, were prepared
asceptically as described previously (Cazaux et al. 1995).
Cells were cultured at a concentration of 1106 cells/ml,
in RPMI 1640 medium (Gibco) supplemented with 10%
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heat-inactivated fetal calf serum (FCS), 2 mM glutamine
and antibiotics – alone or in the presence of optimal
mitogenic concentrations of selective T cell-mitogen,
concanavalin A (Con A, 2 µg/ml) or B cell-mitogen
lipopolysacharide (LPS, 25 µg/ml). Both mitogens were
from Sigma. All cultures were incubated for the indicated
times, as microcultures settled at a final volume of 0·2 ml
in 96-well flat-bottom microtiter plates or as macro-
cultures in T-25 culture flasks (Corning, NY, USA).
Proliferation assays
Proliferation was evaluated by pulses of [3H]thymidine
([3H]TdR, 25 Ci/mmol; New England Nuclear, Perkin
Elmer Inc, Boston, MA, USA) 16 h before the end of the
culture incubation in both microcultures and 0·2 ml
aliquots from the macrocultures, as described previously
(Cazaux et al. 1995). Results were expressed as d.p.m.
values in experimental cultures minus the d.p.m. control
values obtained in cultures of unstimulated cells. When
indicated, PKC blockers were added at the beginning of
cultures and 40 min prior to mitogen addition. It is worth
noting that inhibitors alone do not significantly modify
unstimulated lymphocyte cultures or affect cell viability at
the indicated doses.
Lymphocyte subset determination by flow cytometry
CD4 T-helper/inducer and CD8 T-cytotoxic/suppressor
lymphocytes were determined in lymph nodes or spleen
cell suspensions by flow cytometry. Briefly, aliquots of cell
suspensions (1106) were stained with both fluorescein-
conjugated anti-mouse CD4 (CD4-FITC) or with
R-phycoerythrin-conjugated anti-mouse CD8 (CD8-PE)
monoclonal antibodies. Lymphocytes were identified by
FACS analysis using a FACScan flow cytometer (Becton
Dickinson, Franklin Lakes, NJ, USA) with log amplifi-
cation and FACScan research software. Optimal amounts
of antibodies were used and 8000–10 000 events were
analysed per tube. Dot plots of two color fluorescence
analysis as well as percentages of lymphocytes expressing
CD4 and CD8 were determined. Isotype controls (IgG1-
FITC/IgG2a-PE) were used for each assay to determine
non-specific staining.
HPT axis evaluation
Serum levels of T3 and T4 were determined with
commercial RIA kits (Diagnostic Products Corporation,
Los Angeles, CA, USA) according to manufacturer’s
instructions. TSH serum levels were determined by a RIA
methodology developed in our laboratory using anti-
murine TSH (AFP98991) antibody, rat TSH for iodina-
tion (rTSH-I-9) and mouse TSH reference preparation
(AFP98991) as standards (reagents kindly provided by Dr
A F Parlow from the National Hormone and Peptide
Program, Bethesda, MD, USA). Hypothalamic TSH-
releasing hormone (TRH) was determined by RIA
as described elsewhere (García et al. 1992). Briefly, animals
were killed by decapitation and brains were rapidly
removed. The diencephalic region of each animal was
rapidly dissected with the aid of a stereotaxic atlas. In
order to avoid the degradation of authentic TRH and
the formation of TRH-like substances, samples (one
diencephalum) were boiled in 2 M acetic acid–100 mM
HCl for 20 min, homogenized and centrifuged at
10 000 g for 10 min. The supernatants were lyophilized
and residues dissolved in RIA buffer. The polyclonal
anti-TRH antibody was raised in New Zealand White
rabbits immunized with TRH coupled to BSA using the
bis-diazotized benzidine reaction. Standards or samples
were incubated with [125I]-labeled TRH and anti-TRH
antibody (1/10 000) at 4 C overnight. Bound hormone
was pelleted with rabbit normal serum and a second
antibody against rabbit IgG. All samples were assayed in
duplicate. The minimum detectable amount was 5–10 pg.
Intra- and inter-assay coefficients of variation were less
than 7·0 and 14·0% respectively.
PKC determination
T or B lymphocytes from normal, hypothyroid or hyper-
thyroid mice were incubated alone or in the presence of
Con A (2 µg/ml) or LPS (25µg/ml) for 10 min and were
immediately frozen at a concentration of 1107 cells/
sample in liquid N2. PKC was purified from subcellular
fractions as previously described (Gorelik et al. 2002).
PKC activity was assayed by measuring the incorporation
of 32P from [-32P]-ATP into histone H1. Incubations
were conducted in a final volume of 85 µl at 30 C for
30 min. In the final concentrations, the assay mixture
contained 25 mM ATP (0·4 mCi), 10 mM magnesium
acetate, 5 mM -mercaptoethanol, 50 mg histone H1,
20 mM HEPES, pH 7·5, and, unless otherwise indicated,
0·2 mM CaCl2 and 10 mg/ml of phosphatidylserine ves-
icles. The incorporation of [32P]phosphate into histone
was linear for at least 30 min. The reaction was stopped by
the addition of 2 ml ice-cold 5% trichloroacetic acid with
10 mM H3PO4. The radioactivity retained on GF/C glass
fiber filters after filtration was determined by counting the
filters in 2 ml scintillation fluid. PKC activity was deter-
mined after subtracting the 32P incorporation in the
absence of Ca2+ and phospholipids. Data were expressed
as picomoles of phosphate incorporated into the
substrate per minute and per 107 cells (pmol/min per
107 cells). Alternatively, the PKC enzyme assay system kit
(Amersham) was also used to measure the PKC activity of
subcellular lymphoid fractions, according to the manu-
facturer’s instructions. Where indicated the content of
PKC in samples was calculated by interpolating the
phosphorylation rate (pmol/min) of the samples in a dose–
response curve obtained with PKC purified from rat brain.
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Measurement of cytokine levels
Cytokine levels were determined in culture supernatants
of phytohaemaggulinin (PHA)-stimulated lymph node
cells from euthyroid, hyperthyroid or hypothyroid mice.
Briefly, lymph node cells (5106) were cultured as
indicated above alone or in the presence of 25 µg/ml PHA
for 24 or 48 h. Supernatants were harvested and stored at
80 C before the assay was carried out. Cytokine levels
in supernatants were measured by ELISA, according to the
manufacturer’s instructions (Pierce Endogen, Hercules,
CA, USA). 3,3,5,5-Tetramethylbenzidine was used to
develop the color reaction. The absorbance was recorded
at 450 nm by a microplate reader (model 550; BioRad).
Cytokine concentrations were calculated based on a
standard curve created using standard murine cytokines.
Cytokines released after immunization and in vitro
re-stimulation of spleen cells from mice challenged with
SRBCs were also measured. For this purpose mice were
immunized with SRBCs (0·1 ml of 2·5% SRBCs intra-
peritoneally) and on the seventh day spleen cell suspen-
sions were obtained, treated with 0·83% ammonium
chloride to lyse red blood cells, and cultured for 24 or 48 h
in the absence or presence of 1% SRBCs in cultures.
Supernatants were harvested and cytokine levels were
determined as indicated previously.
Alternatively, animals were sensitized with LPS (one
intraperitoneal injection of 20 µg LPS per mouse, 1 mg/
kg) as described before for developing inflammation (Xue
et al. 2005). After 5 days, spleen cell suspensions were
depleted of red blood cells and were restimulated in vitro
with 1 µg/ml LPS for 24 h. Cytokine levels were
determined in cell-free supernatants of these cultures.
Statistical analysis
Student’s t-test for unpaired values was used to determine
the levels of significance. When multiple comparisons
were necessary after ANOVA, Student–Newman–
Keuls test was applied. Differences between means were
considered significant if P0·05.
Results
Mitogen-induced proliferative responses in lymphocytes from
mice with differing thyroidal status
Selective mitogen-induced proliferative responses were
studied in lymphocytes from euthyroid, hypothyroid and
hyperthyroid mice. Figure 1 shows the time course of
stimulation with Con A (Fig. 1A) or LPS (Fig. 1B), in
lymph node and spleen lymphocytes respectively from
animals with differing thyroid status. Hyperthyroid mice
displayed higher [3H]TdR incorporation, while hypothy-
roid mice displayed lower [3H]TdR uptake, than control
euthyroid animals. Reversion from hypothyroid state by
T3 administration recovered proliferative responses reach-
ing dpm values similar to those obtained in controls. As
shown in Table 1, both T3 and T4 serum levels in these
animals were higher in T4-treated animals and lower in
PTU-treated animals, while levels of T3 hormone re-
Figure 1 Effect of in vivo modulation of thyroid hormone levels on T and B lymphocyte proliferative activity.
Lymph node or spleen cells were obtained from control (Normal, d) or from animals treated with T4 (),
PTU () or PTU+T3 (). Cells (1106 cells/ml) were cultured in RPMI 1640 medium with 10% FCS and
antibiotics in the absence or presence of the T- or B-selective mitogens (Con A (2 g/ml) or LPS (15 g/ml)
respectively) for the indicated times. Proliferation was evaluated by [3H]TdR incorporation as indicated in
Materials and Methods. Results shown are the mean d.p.m. values 	S.E.M. of six experiments performed in
triplicate.
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verted to normal values in T3-injected, PTU-treated
mice. TSH serum levels were above basal values in
hypothyroid mice, an effect that was reverted by T3
treatment, while almost undetectable TSH values were
found in hyperthyroid animals. In addition, hypothalamic
TRH levels were found to be increased in hypothyroid
mice, but decreased in hyperthyroid mice, when com-
pared with control animals.
From these results a clear relationship is demonstrated
among thyroid hormone balance, with special reference to
T3 serum levels and lymphocyte proliferation.
Lymphocyte subsets and thyroid status
To determine if the modulation of lymphocyte prolifer-
ation by thyroid status is related to differences in the
lymphoid subset balance, lymphocyte subsets were ana-
lyzed by dual-flow cytometry using monoclonal anti-
bodies specific for CD4 and CD8 markers. As shown in
Fig. 2 and Table 2, no differences were found among
CD4+, CD8+ and dual-negative cells nor in the CD4/
CD8 ratio in lymphocytes from euthyroid, hyperthyroid,
hypothyroid or PTU+T3-treated mice, thus indicating
that differences in the lymphocyte proliferative pattern
would be mainly related to cellular activation.
Membrane PKC content and mitogen-induced translocation in
lymphocytes from animals with differing thyroid status
Since differences in proliferative responses could be due to
modifications in intracellular signals, activation of PKC,
one of the main enzymatic pathways involved in both T
and B cell proliferation, was determined. As shown in
Figs 3 and 4, both total PKC content, as well as mitogen-
induced PKC translocation, were higher in T and B cells
from hyperthyroid mice and lower in cells from hypothyroid
mice, as compared with controls. Furthermore, T3 treat-
ment of hypothyroid mice was able to reverse the PTU-
induced effects on PKC content and membrane activity.
It is worth noting that PKC blockers, staurosporine and
the more potent and specific inhibitor GF109203X, were
able to inhibit mitogen-induced proliferation of both T
and B cells (Table 3).
Cytokine levels in animals with differing thyroid status in
response to antigen challenge or inflammatory stimulus
In order to further analyze the influence of thyroid
hormone status in biologically relevant situations, such as











Vehicle 110	8 4·3	0·3 45	4 625	50
T4 347	43* 18·4	1·3* <20 309	38*
PTU 62	4* 1·1	0·1* 61	4* 1348	132*
PTU+T3 126	20† 1·2	0·3* 40	5† ND
aMice (n=20 in each group) were treated as indicated in Materials and Methods to obtain euthyroid
(vehicle), hyperthyroid (T4), hypothyroid (PTU) or hypothyroid reverted with T3 (PTU+T3) conditions.
bSerum thyroid hormone and TSH levels, and paraventricular TRH levels, were measured by RIA as
indicated before; results shown are the mean	S.E.M. for each group.
*Differs significantly from the corresponding euthyroid mice with at least P<0·05.
†Differs from the corresponding PTU-treated mice with P<0·05.
Figure 2 Surface expression of CD4+ and CD8+ on lymph node
cells from normal, T4-, PTU- and PTU+T3-treated mice, as
analysed by dual-wave flow cytometry. Cells (1106) from
normal, T4, PTU or PTU+T3 lymph nodes were labeled with both
monoclonal anti-mouse CD4-FITC and CD8-R-PE-conjugated
antibodies. Representative (n=6) dot plots of two-color
fluorescence analysis are shown. Dots representing cells carrying
CD8+ marker only lie along the y-axis, while CD4+ cells lie along the
x-axis. Between 8000 and 10 000 events were analyzed per tube.
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antigen challenge or inflammation, key cytokine levels
(namely IL-2, IFN- and IL-6) were determined after
in vivo administration of SRBCs or LPS and in vitro
re-stimulation. As can be seen in Fig. 5, IL-2 and IFN-
release are increased in hyperthyroid lymphocytes while
decreased in hypothyroid cells with respect to control after
T cell-dependent antigen challenge with SRBC. How-
ever no differences were observed in IL-6 levels. Similar
effects were obtained when stimulating T cells from
non-immunized animals in vitro with PHA.
When animals were injected with the inflammatory
dose of LPS, 80% of hyperthyroid mice died. Figure 5
depicts the cytokines levels in the remaining animals as
well as those from control and hypothyroid mice after in
vitro re-stimulation. No changes were found in IL-2 levels
while increased release of IL-6 and IFN- was observed
only in hyperthyroid animals.
Discussion
Despite the important role assigned to thyroid hormones
in maintaining immune system homeostasis (Foster et al.
2000, Dorshkind & Horseman 2001), their participation
in the regulation of the immune response is still contro-
versial. In addition, a complete analysis of the HPT axis is
lacking in those studies investigating the interaction
between thyroid status and immunity. Furthermore, the
modulation of intracellular signals in lymphocytes by
in vivo fluctuations of thyroid hormones has not been
previously studied. To clarify the role of the HPT axis in
lymphocyte activity, experimental models of hyper- and
hypothyroidism, as well as reversion of the PTU-induced
hypothyroid state by T3 administration, were used and
both thyroid axis and lymphocytes proliferation were
evaluated. The biological significance of the thyroid axis
Table 2 CD4+ and CD8+ percentages, CD4+/CD8+ ratios and percentage of
double-negative in lymph nodes from normal (None), T4-, PTU- and PTU+T3-treated mice
CD4+/CD8+ % CD4+ % CD8+ CD4/CD8
Treatment
None 2·2	0·3 52·2	3·1 24·6	2·0 20·8	2·1
T4 1·8	0·2 49·7	1·5 25·7	1·2 22·5	1·8
PTU 2·3	0·3 51·3	3·7 23·1	2·6 23·1	3·2
PTU+T3 2·6	0·2 55·8	3·5 21·1	0·4 20·2	2·8
Double-positive cells never exceeded 0·5%. Results are the mean	S.E.M. from six individual
determinations. Non-statistically significant differences were found among groups by
Student–Newman–Keuls test applied after ANOVA. It is worth noting that similar results were obtained
on similar amounts of spleen cells from all experimental animal conditions.
Figure 3 Total PKC content in B and T lymphocytes from animals with differing thyroid status. Total PKC
was purified from T (A) or B (B) lymphocytes obtained from control (Normal) mice or from animals treated
with T4, PTU or PTU+T3. PKC activity was measured as indicated and the content of PKC was calculated
by interpolating the phosphorylation rate (pmol/min) of the samples in a dose–response curve obtained
with PKC purified from rat brain. Results shown are the mean	S.E.M. of four experiments performed in
duplicate. *Differs significantly from the corresponding normal values with at least P<0·05. #Differs
significantly from the corresponding PTU values with at least P<0·05.
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Figure 4 Differences in mitogen-induced PKC translocation to particulate fractions in lymphocytes from animals with differing
thyroid status. PKC activity was purified from subcellular cytosol and membrane fractions from normal, T4-, PTU- or
PTU+T3-treated T or B lymphocytes assayed with histone H1 as substrate. Results shown are the mean	S.E.M. of three experiments
performed in duplicate. *Differs significantly from the corresponding basal values with P<0·01; #Differs from the corresponding
values of normal animals with at least P<0·05.
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modulation of lymphocyte function was also evaluated
through the measurement of key cytokine release induced
by antigen challenge.
Hypothryroid mice displayed both low serum levels of
T3 and T4 and high serum TSH and hypothalamic TRH
content, thus indicating that the duration and dose of
PTU treatment used were appropriate for evaluating the
action of low thyroidal status on immunity. It is worth
noting that this dose of PTU is in the range of the
minimum maintenance dose recently proposed for main-
taining euthyroid status in Graves’ disease (Kashiwai et al.
2003). In these conditions, lower proliferative responses to
T- and B-selective mitogens were found compared with
euthyroid control mice. These results were not due to the
immunosuppressive effects assigned to anti-thyroid drugs.
In fact, PTU was demonstrated to interfere directly with
mitogenic activation of lymphocytes only at drug concen-
trations that highly exceed those found in blood samples
of patients treated for hyperthyroidism (Hallengren et al.
1980). In addition, the mechanism of their action was
proposed to be indirect, through the diminished produc-
tion of thyroid hormones (Volpe 2001). Reversion of
PTU treatment with T3, increased T3 but not T4 levels,
and decreased TSH to levels found in controls, an effect
that was accompanied by a recovery in proliferative
responses to both T- and B-selective mitogens. It is worth
noting that T3 reversion of anti-thyroid PTU treatment
has been demonstrated to maintain low levels of T4 by
other authors using similar drug administration schedules
(Nishida & Kawada 1992, Weiss et al. 1999), thus indi-
cating that T3 is the thyroid hormone responsible for
regulating lymphocyte activity. On the other hand,
hyperthyroid mice showed high serum levels of T3 and
T4, with undetectable levels of TSH, low levels of TRH
and higher proliferative responses than controls. Non-
statistically significant differences in the kinetic course of
T and B cell responses were found among groups.
In accordance with our results, a decrease in the
proliferative responses to either T cell (Con A and PHA)
or B cell (pokeweed mitogen (PWM)) mitogens in splenic
and peripheral blood lymphocytes from hypothyroid ani-
mals (Chatterjee & Chandel 1983, Fabris et al. 1995) has
been previously reported. Furthermore, T3 administration
was found to restore lymphocyte blastogenic responses in
thyroidectomized rats (Chatterjee & Chandel 1983). In
addition, negative or positive modulation of cellular
alloimmune responses was described in hypo- or hyper-
thyroid mice respectively (Klecha et al. 2000). Blastogenic
responses to T and B cell mitogens were also found to be
Table 3 Effect of PKC blockers on mitogen-induced proliferation of
both T and B cells from normal, T4 or PTU mice
Proliferation (% of control)a
Staurosporine (2 nM) GF109203X (1 M)
T cells B cells T cells B cells
Treatment
None 15	2 20	3 24	3 28	4
T4 22	3 21	4 31	3 27	4
PTU 7	3 11	2 19	4 20	3
aCells were incubated with blockers and mitogens as indicated perviously
and results are expressed as percentage of d.p.m. in mitogen-stimulated
cultures without blocker. Results are the mean	S.E.M. of three experiments
performed in triplicate.
Figure 5 Cytokine levels from normal, hypothyroid (PTU) and
hyperthyroid (T4) cells after antigenic challenge. IL-2, IFN- and
IL-6 levels were measured in cell-free supernatants from spleen
cells after re-stimulation in vitro with SRBCs or LPS, or lymph node
cells after PHA stimulation as described in Materials and Methods.
Results shown are the mean	S.E.M. values of at least five animals
of each experimental group. *Differs significantly from normal
animals with at least P<0·05.
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increased following T3 or T4 administration (Chatterjee
& Chandel 1983), with the T mitogenic response being
significant after 1 month of treatment, similar to the
duration of T4 administration in our study.
TSH has been shown to have a variety of immune-
regulating cytokine-like activities that can affect the
magnitude of antibody and cell-mediated responses of
peripheral lymphocytes (Wang & Klein 2001, Klein
2003). In fact, a TSH-mediated up-regulation of the
mouse lymphocyte proliferative response to both Con A
and PHA has been reported (Provinciali et al. 1992). With
respect to TRH, it was suggested that this hormone exerts
both direct and indirect effects on the immune system.
Acute and chronic administration of TRH enhances the
proliferation of splenic and thymic lymphocytes in rats
(Winczyk & Pawlikowski 2000). Finally, TRH admin-
istration in humans led to increased secretion of IL-2 into
the blood (Komorowski et al. 1994). Although in vitro
findings allow us to conclude that TSH and TRH
enhance lymphocyte activity, the major concern with
in vivo studies is to know whether their effects on immune
responses are direct or are related to their regulation of the
secretion of thyroid hormones. Our results for enhanced
lymphoid responses, achieved with high levels of T3 and
T4, but low levels of TSH and TRH – and with the
converse in hypothyroid conditions – strengthened the
possibility that levels of thyroid hormones modulate
lymphocyte reactivity independently of TSH and
TRH levels.
Changes in T helper/inducer (CD4+) and T cytotoxic
(CD8+) cells are related to some pathologies that have
alteration in both immune function and thyroid hormone
levels – such as Down’s syndrome, depression, and
immune and non-immune thyroid diseases (Licastro et al.
2001, Bossowski et al. 2003). Therefore, we determined
CD4/CD8 ratios in animals with differing thyroid status.
Our results indicate that there were no significant varia-
tions in CD4+ and CD8+ cell counts in lymphoid
compartments among euthyroid, hyperthyroid, hypothy-
roid or PTU+T3-treated animals. Similar results were
found in children with non-immune thyroid disease or in
euthyroid autoimmune Graves’ patients (Bossowski et al.
2003). An abnormal distribution of B, T and T cell subsets
in immune thyroid disorders would be related to auto-
immunity development. On other hand, changes in
hypo- and hyperthyroid T or B lymphocyte proliferative
responses would not be a consequence of modifications of
lymphocyte subset distribution, but would rather be
related to cellular activation.
Lymphocytes from hyperthyroid mice displayed an
increase in both total PKC cellular levels and mitogen-
induced PKC translocation. In contrast, a decrease in
these parameters was observed in hypothyroid animals.
PKC blockers, staurosporine and GF103209X inhibit
mitogen-induced proliferation in lymphocytes from
control, hypo- and hyperthyroid mice similarly,
thus indicating the importance of this enzymatic pathway.
These results show, for the first time, thyroid hormone-
mediated regulation of PKC content in lymphocytes,
which could be involved in altered responsiveness to
mitogen-induced stimulation of proliferative responses. In
support of our results, thyroid hormone modulation of
PKC activity has been demonstrated in non-lymphoid
tissues (Meier et al. 1991, Shimoni 1999, Pantos et al.
2001, Wong et al. 2001) and would probably indicate a
genomic up-regulation of enzyme expression and/or
function induced by thyroid hormones in lymphoid cells
(Yen 2001).
In order to ascertain the importance of thyroid hor-
mone actions on lymphocyte activity, key cytokine levels
were determined after antigen challenge. For this purpose
we evaluated IL-2 (a crucial cytokine for lymphocyte
proliferation and activation), IFN- (a Th1 cytokine
important for cellular immunity) and the proinflammatory
Th2 IL-6 cytokine (involved in promoting specific im-
mune responses). Cells from hyperthyroid mice responded
to the T cell-dependent antigen SRBC and to PHA by
increasing IL-2 and IFN- secretion, while cells from
hypothyroid mice responded by decreasing IL-2 and
IFN- secretion, compared with control euthyroid cells.
No differences were found for IL-6 levels, thus indicating
the modulation by thyroid status of important cytokines
related to cellular immunity. When injected with an
inflammatory dose of LPS, most (80%) hyperthyroid mice,
but not control or hypothyroid mice, died of disseminated
intravascular coagulation and multi-organ dysfunction, as
shown by anatomical observation of animals during
autopsy (data not shown). This would probably mean that
this dose of LPS induced an endotoxic shock in hyper-
thyroid mice. Furthermore, high levels of the proinflam-
matory IL-6 cytokine were found in these animals. Similar
to our results, a decrease in IL-2 levels after Con A
stimulation of spleen cells was found in hypothyroid mice
(Liu et al. 1995). However, Karanikas et al. (2004) found
no differences in cytokine pattern in the sera of patients
with non-immune severe hypothyroidism. When these
results are considered together, it seems that thyroid
hormones do not affect basal cytokine production but
would change lymphocyte reactivity against any immune
stimuli. Data regarding cytokine patterns in hyperthyroid
status come from experimental models of Graves’ disease
and are all related to the development of autoimmunity.
There are no available data on cytokine measurements in
non-immune hyperthyroidism. Finally, our results indi-
cate the important role of thyroid hormones in regulating
lymphocyte reactivity, thus reinforcing the fact that sus-
tained suppression of hormone levels would have deleteri-
ous biological effects on the overall ability of the host to
generate a strong immune response. Moreover, these
results form the basis for future research, proposing the
regulation of thyroid hormone levels in pathologies with
immunological abnormalities.
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